Ixaka

Ixaka is a privately-owned cell and gene therapy company based in the UK, with operations in the UK, Spain, and France. The company focuses on harnessing the body's natural power to heal diseases.Our proprietary technology enhances the intrinsic therapeutic potential of cells by targeting healing cells to the site of disease and improving their therapeutic effects through direct in vivo modification.Ixaka’s technologies – Concentrated Multicellular Therapy and Targeted Nanoparticles – demonstrate potential in treating a wide range of serious conditions, including oncology, cardiovascular, neurological, and ocular diseases, as well as genetic disorders.